|
 |
| home > pmps > spring 2007 > bespoke code reading – a prescription for less confusion, |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
| Richard Laight and Charlie Plain-Jones at Absolute Vision address the role of bespoke packaging and labelling in the pharmaceutical industry
The need for bespoke packaging and labelling in the pharmaceutical market place is becoming ever greater. This is due to a number of factors, including an increase in legislation. This legislation not only requires manufacturers to ensure full and detailed product labelling, which, in itself, must provide information for the end user, for example date of production and expiry, but also information capable of providing a traceable history for that particular batch. The second factor that is having an impact on packaging and labelling in the pharmaceutical industry is the change in production and distribution processes in response to evolving so called ‘borderless’ and global markets.
IMPACT ON THE INDUSTRY
A high percentage of medicines returned to manufacturers by the distribution chain are returned – not because they are faulty but because they have been packaged incorrectly, possibly in the wrong language or with the wrong product name for that specific market or with a basic error, such as an incorrect dosage level. With the majority of pharmaceutical items there are three distinct parts to the packaging:
- The bottle on the label or on the foil surrounding the tablet or pill
- The printed insert giving details of dosage, side effects and so on
- The final external protective carton or box that is displayed on the chemist’s shelf
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Richard Laight is co-founder and Business Development Manager of Absolute Vision Ltd, a specialist developer of data matrix and optical character reading solutions. Richard has over 22 years’ experience of working in the computer industry, primarily in a software development role. His career began in the public sector, working on the development of educational software under a crown copyright for national schools and colleges. Later, Richard moved into the corporate sector and was involved in the deployment of large networks into blue-chip companies and qualified as a Novell and Microsoft Certified Network Engineer (CNE). Richard set up Absolute Vision Ltd with colleague Peter Greenrod to develop their mutual interests in machine vision. The business was incorporated in February 2001 and began trading in June 2001.
Charlie Plain-Jones joined Absolute Vision in June 2003 to lead the company’s expansion programme in quality-driven industries; such as aerospace, automotive, electronics and healthcare. Charlie has spent 20 years in sales and business development for mainly US-based corporations, migrating leading-edge technologies into Europe. Charlie is experienced in a number of automated manufacturing processes, and, most recently, he has worked in the European business development of advanced Data Matrix 2D symbology reading systems. Charlie has taken an active role in defining relevant standards within these industries. Working in Europe and the near-East, Charlie has been involved in large-scale implementation programmes in several industries. Charlie gained an honours degree in Electronic Engineering at the University College of North Wales (UCNW). |
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Aegate Proves Authenticating Drugs at the Point of Dispensing Protects Consumers
More info >> |
|
 |
